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Summary
Background Based on previous findings, we hypothesised that radiotherapy to the prostate would improve overall 
survival in men with metastatic prostate cancer, and that the benefit would be greatest in patients with a low metastatic 
burden. We aimed to compare standard of care for metastatic prostate cancer, with and without radiotherapy.
Methods We did a randomised controlled phase 3 trial at 117 hospitals in Switzerland and the UK. Eligible patients 
had newly diagnosed metastatic prostate cancer. We randomly allocated patients open-label in a 1:1 ratio to standard 
of care (control group) or standard of care and radiotherapy (radiotherapy group). Randomisation was stratified by 
hospital, age at randomisation, nodal involvement, WHO performance status, planned androgen deprivation therapy, 
planned docetaxel use (from December, 2015), and regular aspirin or non-steroidal anti-inflammatory drug use. 
Standard of care was lifelong androgen deprivation therapy, with up-front docetaxel permitted from December, 2015. 
Men allocated radiotherapy received either a daily (55 Gy in 20 fractions over 4 weeks) or weekly (36 Gy in six fractions 
over 6 weeks) schedule that was nominated before randomisation. The primary outcome was overall survival, 
measured as the number of deaths; this analysis had 90% power with a one-sided α of 2·5% for a hazard ratio (HR) 
of 0·75. Secondary outcomes were failure-free survival, progression-free survival, metastatic progression-free survival, 
prostate cancer-specific survival, and symptomatic local event-free survival. Analyses used Cox proportional hazards 
and flexible parametric models, adjusted for stratification factors. The primary outcome analysis was by intention to 
treat. Two prespecified subgroup analyses tested the effects of prostate radiotherapy by baseline metastatic burden 
and radiotherapy schedule. This trial is registered with ClinicalTrials.gov, number NCT00268476.
Findings Between Jan 22, 2013, and Sept 2, 2016, 2061 men underwent randomisation, 1029 were allocated the control 
and 1032 radiotherapy. Allocated groups were balanced, with a median age of 68 years (IQR 63–73) and median 
amount of prostate-specific antigen of 97 ng/mL (33–315). 367 (18%) patients received early docetaxel. 1082 (52%) 
participants nominated the daily radiotherapy schedule before randomisation and 979 (48%) the weekly schedule. 
819 (40%) men had a low metastatic burden, 1120 (54%) had a high metastatic burden, and the metastatic burden was 
unknown for 122 (6%). Radiotherapy improved failure-free survival (HR 0·76, 95% CI 0·68–0·84; p<0·0001) but not 
overall survival (0·92, 0·80–1·06; p=0·266). Radiotherapy was well tolerated, with 48 (5%) adverse events (Radiation 
Therapy Oncology Group grade 3–4) reported during radiotherapy and 37 (4%) after radiotherapy. The proportion 
reporting at least one severe adverse event (Common Terminology Criteria for Adverse Events grade 3 or worse) was 
similar by treatment group in the safety population (398 [38%] with control and 380 [39%] with radiotherapy).
Interpretation Radiotherapy to the prostate did not improve overall survival for unselected patients with newly 
diagnosed metastatic prostate cancer.
Funding Cancer Research UK, UK Medical Research Council, Swiss Group for Clinical Cancer Research, Astellas, 
Clovis Oncology, Janssen, Novartis, Pfizer, and Sanofi-Aventis.
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
Patients with metastatic cancer typically receive systemic 
treatment, with local therapy reserved—if required—for 
symptom palliation. However, local treatment to the 
primary tumour might be more useful than previously 
appreciated. In animal models of cancer, primary 
tumours metastasise not merely by disseminating 
tumour cells into the circulation but also by priming the 
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premetastatic niche.1 Proliferation of tumour cells at 
distant sites to form overt metastases is dependent on 
compounds secreted by the primary tumour into the 
circulation.2 In these models, local treatment of the 
primary tumour inhibits not just the initiation of distant 
disease but also the progression of existing metastases.
Radical local treatment of the primary tumour has been 
tested in several randomised controlled trials in patients 
with metastatic cancer. Cytoreductive nephrectomy 
improved survival in patients with metastatic renal carcin­
oma,3,4 but this benefit was not confirmed in a more 
recent trial in patients with advanced disease.5 Radio­
therapy to the primary tumour has not been shown to 
improve survival in patients with metastatic small­cell 
lung cancer6 or metastatic breast cancer,7 but these trials 
were relatively small and might not have detected a 
modest, but worthwhile, benefit.
In men with metastatic prostate cancer, retrospective 
analyses have noted an association between use of 
radiotherapy to the primary tumour and improved overall 
survival.8–11 The survival benefit associated with prostate 
radiotherapy was reported to be greater in patients with a 
better prognosis.8,9,11 The HORRAD trial randomised 
432 men with metastatic prostate cancer to androgen 
deprivation therapy with or without prostate radiotherapy 
and found no evidence of an overall survival benefit 
(hazard ratio [HR] 0·90, 95% CI 0·70–1·14) but raised 
the possibility that survival might be improved in a 
subgroup of patients with fewer than five bone metastases 
(0·68, 0·42–1·10).12
We hypothesised that radical radiotherapy to the 
prostate would improve overall survival in men 
presenting with metastatic prostate cancer and that the 
survival benefit would be greatest in men with a low 
metastatic burden.
Methods
Study design and participants
We did a randomised controlled phase 3 trial at 
117 hospitals in Switzerland and the UK. Eligible patients 
had prostate cancer that was newly diagnosed, with no 
previous radical treatment, and had metastatic disease 
confirmed on a bone scintigraphic scan and soft­tissue 
imaging done within 12 weeks of starting androgen 
deprivation therapy. All patients were intended for long­
term androgen deprivation therapy and started treatment 
no earlier than 12 weeks before randomisation. There 
were no age restrictions; patients were required to have 
no contra indications to radiotherapy and no clinically 
significant cardiovascular history.
This trial was done in accordance with Good Clinical 
Practice guidelines and the Declaration of Helsinki and 
had relevant regulatory and ethics approvals. All patients 
gave written informed consent. The rationale and design 
have been described previously.13 Full details are in the 
protocol.
Randomisation and masking
Patients were randomised centrally using a computerised 
algorithm, which was developed and maintained by the 
Medical Research Council (MRC) Clinical Trials Unit at 
University College London. Minimisation with a random 
element of 20% was used, stratifying for hospital, age at 
randomisation (<70 years vs ≥70 years), nodal involve­
ment (negative vs positive vs indeterminate), WHO 
perfor m ance status (0 vs 1 or 2), planned androgen 
deprivation therapy, and regular aspirin or non­steroidal 
anti­inflammatory drug use (yes or no). Planned doce­
taxel use was added as a stratification factor on 
Dec 17, 2015. Allocation was 1:1 to either standard of 
care (control) or standard of care and radiotherapy 
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Research in context
Evidence before this study
We searched MEDLINE (1966–2018), Embase (1982–2018), 
trial registers (Cochrane Central Register of Controlled Trials and 
ClinicalTrials.gov), and major urology and oncology conference 
proceedings (1990–2018) to retrieve randomised controlled 
trials of radiotherapy in metastatic prostate cancer. The search 
strategy included a range of terms to identify randomised 
controlled trials, prostate cancer, and radiotherapy. 
One relevant trial—HORRAD—was identified (n=432, 
270 deaths) in which no evidence was reported of an overall 
survival benefit for prostate radiotherapy (hazard ratio 
[HR] 0·90, 95% CI 0·70–1·14), but a hypothesis was generated 
that survival might be improved in a subgroup of patients with 
low metastatic burden (HR 0·68, 95% CI 0·42–1·10).
Added value of this study
To the best of our knowledge, our large randomised trial 
(n=2061, 761 deaths) provides the best available evidence 
about the role of prostate radiotherapy in metastatic prostate 
cancer. Our findings showed no overall survival benefit of 
radiotherapy to the prostate in men with newly diagnosed 
prostate cancer. However, a subgroup analysis supported the 
hypothesis of HORRAD, that prostate radiotherapy improves 
survival in men with low metastatic burden.
Implications of all the available evidence
Evidence suggests that prostate radiotherapy improves 
overall survival for men with metastatic prostate cancer who 
have a low metastatic burden, but not for unselected 
patients. Prostate radiotherapy should be a standard 
treatment option for men with newly diagnosed disease with 
a low metastatic burden.
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(radiotherapy). Patients and clinical and study staff were 
aware of the treatment allocation for practical reasons, 
and the key efficacy outcome measures were objective.
Procedures
All patients received lifelong androgen deprivation therapy 
as either gonadotrophin­releasing hormone agonists or 
antagonists or orchidectomy. Docetaxel was permitted 
in addition to hormone therapy after its approval in the 
UK on Dec 17, 2015. Docetaxel, when used, was given 
as six 3­weekly cycles of 75 mg/m², with or without 
prednisolone 10 mg daily.
External­beam radiotherapy to the prostate was given 
as one of two schedules nominated before randomisation: 
either 36 Gy in six consecutive weekly fractions of 6 Gy, 
or 55 Gy in 20 daily fractions of 2·75 Gy over 4 weeks. 
Radiotherapy was given with the patient supine and with 
a full bladder and an empty rectum. The planning target 
volume consisted of the prostate only, with an 8 mm 
margin posteriorly and a 10 mm margin elsewhere. 
Radiotherapy was to commence as soon as practicable 
after randomisation, and within 3–4 weeks after the last 
docetaxel dose.
Patients were followed up every 6 weeks until 6 months 
after randomisation, then every 12 weeks to 2 years, then 
every 6 months to 5 years, then annually there after. 
Prostate­specific antigen (PSA) levels were measured at 
every follow­up visit; further tests were at the clinician’s 
discretion. Nadir PSA was the lowest level of PSA 
reported within 24 weeks after randomisation. Toxic 
effects and symptoms were reported at regular follow­
up visits or when an adverse event was categorised as 
serious. Adverse events were graded with the National 
Cancer Institute Common Terminology Criteria for 
Adverse Events (CTCAE) version 4.0. Adverse effects 
on the bowel and bladder during radiotherapy, and 
possible long­term effects of radiotherapy, were recorded 
separately in patients assigned standard of care and 
radiotherapy using the Radiation Therapy Oncology 
Group (RTOG) scale.14
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1029 allocated to standard of care 
(control)
20 received radiotherapy 
within 1 year of 
randomisation
1009 did not receive 
radiotherapy within 
1 year of 
randomisation 
976 had metastatic burden 
classified
409 low burden
567 high burden
963 had metastatic burden 
classified
410 low burden
553 high burden
1032 allocated to standard of care 
and radiotherapy
968 received radiotherapy 
within 1 year of 
randomisation
64 did not receive 
radiotherapy within 
1 year of randomisation
582 alive, data in past year
56 alive, no data in past year 
391 died
556 alive, data in past year 
(269 low; 287 high)
52 alive, no data in past year 
(24 low; 28 high)
368 died (116 low; 252 high)
591 alive, data in past year
71 alive; no data in past year 
370 died
562 alive, data in past year 
(293 low; 269 high)
54 alive; no data in past year 
(27 low; 27 high)
347 died (90 low; 257 high)
1029 analysed for efficacy 
1073 had only standard of care   
(1009 control; 64 radiotherapy) 
1050 analysed for safety
988 started radiotherapy 
(20 control; 968 radiotherapy)
976 analysed for efficacy 1032 analysed for efficacy 963 analysed for efficacy 
23 excluded, no adverse event assessment 
(10 control; 13 radiotherapy)
4697 patients randomised to trial platform 
2061 randomly assigned
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985 analysed for safety
3 excluded, no adverse event assessment 
(3 radiotherapy)
2636 allocated to other research arms or 
not eligible as control for this trial
Figure 1: Trial profile
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Metastatic burden at randomisation was assessed 
through whole­body scintigraphy and CT or MRI staging 
scans. Scans were centralised and reviewed by one of us 
(AA), with 10% independent review by a radiologist (HD). 
The metastatic burden was classified according to the 
definition used in the CHAARTED trial:15 high metastatic 
burden was defined as four or more bone metastases with 
one or more outside the vertebral bodies or pelvis, or 
visceral metastases, or both; all other assessable patients 
were considered to have low meta static burden.
Outcomes
The primary efficacy outcome was overall survival, 
defined as time from randomisation to death from any 
cause. Failure­free survival was the primary activity 
outcome measure for interim analyses and was defined 
as time from randomisation to first evidence of at least 
one of: biochemical failure; progression either locally, in 
lymph nodes, or in distant metastases; or death from 
prostate cancer. Biochemical failure was based on a rise 
above the lowest PSA value reported within 24 weeks 
after enrolment of 50% and to at least 4 ng/mL; patients 
without a fall of 50% were considered to have bio­
chemical failure at time zero. Secondary outcomes 
were progression­free survival (defined as failure­free 
survival but without biochemical events) and metastatic 
progression­free survival (defined as time from ran­
domisation to new metastases or pro gression of existing 
metastases or death). Cause of death was determined by 
the site investigator, with some causes reclassified as 
prostate cancer according to predefined criteria that 
indicated prostate cancer to be the likely cause. Symptom­
atic local events were defined as any of the following: 
urinary­tract infection, new urinary catheterisa tion, acute 
kidney injury, tran surethral resection of the prostate, 
urinary­tract obstruction, ureteric stent, neph rostomy, 
colostomy, and surgery for bowel obstruction. Patients 
without the event of interest were censored at the time 
last known to be event­free.
Statistical analysis
This randomised comparison was incorporated within the 
Systemic Therapy for Advanced or Metastatic Prostate 
Control  
(n=1029)
Radiotherapy 
(n=1032)
Age at randomisation (years) 68 (63–73) 68 (63–73)
Range 37–86 45–87
WHO performance status
0 732 (71%) 734 (71%)
1–2 297 (29%) 298 (29%)
Pain from prostate cancer
Absent 820 (81%) 844 (83%)
Present 198 (19%) 170 (17%)
Missing data 11 18
Previous notable health issues
Myocardial infarction 67 (7%) 57 (6%)
Cerebrovascular disease 29 (3%) 30 (3%)
Congestive heart failure 5 (<1%) 8 (1%)
Angina 46 (4%) 51 (5%)
Hypertension 408 (40%) 440 (43%)
Missing data 5 8
T category at randomisation
T0 0 (0%) 2 (<1%)
T1 12 (1%) 12 (1%)
T2 84 (9%) 89 (9%)
T3 585 (62%) 603 (63%)
T4 260 (28%) 246 (26%)
TX 88 80
N category at randomisation
N0 345 (36%) 344 (36%)
N+ 620 (64%) 620 (64%)
NX 64 68
Metastatic burden
Low 409 (42%) 410 (43%)
High 567 (58%) 553 (57%)
Not classified 53 69
(Table 1 continues in next column)
Control  
(n=1029)
Radiotherapy 
(n=1032)
(Continued from previous column)
Sites of metastases
Bone 919 (89%) 917 (89%)
Liver 23 (2%) 19 (2%)
Lung 42 (4%) 48 (5%)
Distant lymph nodes 294 (29%) 304 (29%)
Other 35 (3%) 33 (3%)
Gleason sum score
≤7 173 (17%) 172 (18%)
8–10 820 (83%) 810 (82%)
Unknown 36 50
PSA before androgen 
deprivation therapy (ng/mL)
98 (30–316) 97 (33–313)
Range 1–20 590 1–11 156
Time from diagnosis (days) 73 (55–94) 73 (55–93)
Missing data 7 16
Time from starting hormones 
(days)
52 (35–70) 55 (34–70)
Range –32 to 84 –10 to 85
Missing data 0 1
Planned docetaxel
No 845 (82%) 849 (82%)
Yes 184 (18%) 183 (18%)
Nominated radiotherapy schedule*
Weekly 482 (47%) 497 (48%)
Daily 547 (53%) 535 (52%)
Data are median (IQR) or n (%), unless otherwise stated. PSA=prostate-specific 
antigen. *The weekly schedule was 36 Gy in six fractions over 6 weeks and the 
daily schedule was 55 Gy in 20 fractions over 4 weeks.
Table 1: Baseline characteristics
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cancer: Evaluation of Drug Efficacy (STAMPEDE) multi­
arm multistage (MAMS) platform protocol (appendix p 6). 
It was designed with a seamless phase 2/3 approach.16 The 
sample size was calculated using nstage and its pre decessor 
programs in Stata, which enable design of MAMS trials.17 
Assuming, for the control group, a median failure­free 
survival of roughly 1 year and median survival of about 
3·5 years, we targeted a 25% relative improvement 
(HR 0·75) in both failure­free survival and overall survival 
for the group allocated radiotherapy to the prostate over the 
control group.
For the efficacy stage analysis of the pairwise com­
parison of standard of care and radiotherapy versus 
standard of care for overall survival, approximately 
267 deaths in patients allocated to the control group were 
needed for 90% power and a one­sided α of 2·5%, 
accounting for three intermediate analyses of failure­
free survival (analysed June, 2014, November, 2014, and 
May, 2015). For this comparison, the pairwise and family­
wise error rates were judged very similar, because of the 
limited overlap in events with other reported comparisons 
from the protocol and the non­binding nature of the 
interim analyses.
The initial sample size target was 1250 patients. During 
the trial, weekly and daily radiotherapy schedules were 
nominated approximately equally. Therefore, the sample 
size was increased to roughly 1800, without reference to 
outcome data, to provide good power for failure­free 
survival in each radiotherapy schedule­defined subgroup 
when the comparison reached its target power overall, 
assuming that the effect of radiotherapy would be 
the same regardless of schedule. We predicted about 
300 failure­free survival events in the control group on 
each schedule at the time of the main analysis, which 
would provide approximately 90% power with a one­
sided α of 0·015 to detect an HR of 0·75. The effect of 
radiotherapy on survival within a nominated radiotherapy 
schedule would be investigated if there was both an effect 
on failure­free survival and 200 or more deaths in the 
control group were reported for that nominated schedule.
In May, 2018, based on accumulating external data and 
without reference to any data from this comparison in 
STAMPEDE, we prespecified that any effect from radio­
therapy would be greatest in patients with a low baseline 
metastatic burden and that this hypothesis could be tested 
with reasonable power, regardless of interaction test 
results. If roughly 40% of patients had a low metastatic 
burden, we anticipated more than 90% power for failure­
free survival (HR 0·70) if median failure­free survival were 
24 months in the control group and about 60% power for 
overall survival (HR 0·70) if median survival were roughly 
6 years. If about 60% of patients had a high metastatic 
burden, we anticipated the subgroup analysis would have 
roughly 88% power for failure­free survival (HR 0·80) if 
median failure­free survival were 12 months in the control 
group and about 63% power for overall survival (HR 0·80) 
if median survival were 4 years.
Standard survival analysis methods were used to 
analyse time­to­event data in Stata version 15. A non­
parametric stratified log­rank test was used to detect a 
difference in survival between treatment groups; this 
analysis was stratified across the minimisation factors 
used at randomisation (except hospital and planned 
androgen deprivation therapy) plus protocol­specific 
periods defined by other arms recruiting to STAMPEDE 
or changes to standard of care that could affect the 
population being randomised. Cox proportional hazards 
regression models adjusting for the same stratification 
factors and stratified by time were used to estimate 
relative treatment effects. An HR less than 1·00 favoured 
radiotherapy. Flexible parametric models were fitted with 
degrees of freedom (5,5) and adjusted for stratification 
factors and time.18 Medians and 3­year survival estimates 
are presented from the flexible parametric models fitted 
A Overall survival
B Failure-free survival
Number at risk
(events)
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Radiotherapy
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1032 998 936 832 611 478 365 236 128 47
1029 998 933 826 601 481 328 219 122 41
Number at risk
(events)
Control
Radiotherapy
0 6 12 18 24 30 36 42 48 54
Time since randomisation (months)
0
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 (%
)
1032 799 588 440 285 212 156 101 48 18
1029 711 516 380 216 149 99 58 31 11
HR 0·76, 95% CI 0·68–0·84; p<0·0001
HR 0·92, 95% CI 0·80–1·06; p=0·266
Control
Radiotherapy
(17)
(12)
(56)
(47)
(82)
(64)
(63)
(75)
(39)
(54)
(67)
(41)
(37)
(37)
 (16)
 (25)
(9)
(11)
(1)
(3)(14)
(8)(13)
(11)
(25)
(20)
(26)
(33)
 (76)
 (70)
(119)
(120)
(189)
(203)
(300)
(211)
Figure 2: Overall survival and failure-free survival, by treatment
HR=hazard ratio. Solid lines show the Kaplan-Meier analysis and dotted lines show the flexible parametric model.
See Online for appendix
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to the data; these are more reliable than reading the 
Kaplan­Meier curves; graphs show estimated survival 
over time from both. The proportional hazards assump­
tion was tested; restricted mean survival time was 
emphasised in the presence of non­proportionality, using 
a t­star of 59 months as determined by the Royston and 
Parmar method.18 Cause­specific and Fine and Gray 
regression models19 were used for competing risk analysis 
of prostate cancer­specific, lymph node, and meta static 
progression­free and symptomatic local event­free 
survival. All tests are presented as two­sided, with 
95% CIs and relevant p values.
Subgroup analyses were prespecified for the nominated 
radiotherapy schedule (daily vs weekly) and for baseline 
metastatic burden (low vs high), when determinable. 
Exploratory interaction analyses considered the con­
sistency of treatment effect within stratification factors, 
by time, by Gleason score, and by PSA before hormone 
therapy.
Median follow­up was ascertained by reverse­censoring 
on death. All patients were included in the primary 
efficacy analysis according to allocated treatment, and the 
analysis was done on an intention­to­treat basis. Adverse 
event data are shown for the safety population, which 
consisted of patients with at least one follow­up 
assessment analysed according to the treatment approach 
started; patients were excluded if they had no adverse 
event data. A sensitivity analysis was done on an intention­
to­treat basis. Data for symptomatic local events are also 
presented. All other analyses are exploratory.
Accumulating interim data were reviewed by an 
Independent Data Monitoring Committee, guided by 
lack­of­benefit stopping guidelines.
This trial is registered at ClinicalTrials.gov (number 
NCT00268476) and ISRCTN.com (ISRCTN78818544).
Role of the funding source
MRC employees contributed to study design, data 
collection, data analysis, data interpretation, and writing 
of this report. CDB, MRS, APH, and AA had access to 
raw data. The corresponding author had final respon­
sibility for the decision to submit for publication.
Results
Between Jan 22, 2013, and Sept 2, 2016, 2061 patients 
were randomly allocated either standard of care 
Adjusted hazard 
ratio (95% CI)
Survival at 3 years* Restricted mean survival time  
(months)*
Control Radiotherapy Control Radiotherapy Difference (95% CI)
Overall survival
All patients 0·92 (0·80–1·06) 62% 65% 41·6 42·5 1·0 (–0·6 to 2·5)
Low metastatic burden 0·68 (0·52–0·90) 73% 81% 45·4 49·1 3·6 (1·0 to 6·2)
High metastatic burden 1·07 (0·90–1·28) 54% 53% 38·8 37·6 –1·2 (–3·5 to 1·1)
Failure-free survival
All patients 0·76 (0·68–0·84) 23% 32% 21·4 26·2 4·8 (2·8 to 6·7)
Low metastatic burden 0·59 (0·49–0·72) 33% 50% 27·4 36·1 8·6 (5·6 to 11·7)
High metastatic burden 0·88 (0·77–1·01) 17% 18% 17·3 18·8 1·5 (–0·7 to 3·6)
Progression-free survival
All patients 0·96 (0·85–1·08) 44% 44% 32·4 33·1 0·7 (–0·9 to 2·3)
Low metastatic burden 0·78 (0·63–0·98) 58% 63% 39·4 42·9 3·5 (0·4 to 6·7)
High metastatic burden 1·09 (0·94–1·26) 35% 30% 28·0 26·2 –1·8 (–4·3 to 0·8)
Metastatic progression-free survival
All patients 0·97 (0·86–1·10) 47% 47% 33·9 34·4 0·4 (–1·5 to 2·4)
Low metastatic burden 0·80 (0·63–1·01) 62% 67% 41·1 44·2 3·1 (0·2 to 6·0)
High metastatic burden 1·10 (0·95–1·28) 37% 33% 29·3 27·3 –2·0 (–4·7 to 0·7)
Prostate cancer-specific survival
All patients† 0·93 (0·80–1·09) 66% 69% 43·9 44·6 0·7 (–1·1 to 2·5)
Low metastatic burden 0·65 (0·47–0·90) 79% 86% 48·6 51·8 3·3 (1·0 to 5·5)
High metastatic burden 1·10 (0·92–1·32) 58% 56% 40·6 39·0 –1·6 (–3·9 to 0·7)
Symptomatic local event-free survival
All patients 1·07 (0·93–1·22) 57% 55% 38·2 37·2 –1·1 (–3·1 to 0·9)
Low metastatic burden 0·82 (0·64–1·05) 65% 72% 41·6 44·0 2·4 (–0·7 to 5·4)
High metastatic burden 1·23 (1·05–1·46) 50% 43% 35·8 32·2 –3·6 (–6·2 to –1·0)
Hazard ratio and restricted mean survival time differences are for radiotherapy relative to control. *Survival probabilities and restricted mean survival time estimates are 
taken from flexible parametric models (t-star, 59 months). †Competing risks analysis, sub-hazard ratio 0·94, 95% CI 0·81–1·10; p=0·431.
Table 2: Summary of estimated treatment effect for main outcome measures, for all patients and by metastatic burden
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(control group, n=1029) or standard of care and radio­
therapy (radiotherapy group, n=1032; figure 1). Groups 
were well balanced with respect to baseline characteristics 
(table 1). Median age was 68 years (IQR 63–73) and 
median PSA before androgen deprivation therapy was 
97 ng/mL (33–315). 1630 (79%) patients had a Gleason 
score of 8–10. 1836 (89%) had bone metastases. 1466 (71%) 
had a WHO performance status of zero. Baseline 
characteristics of 1939 (94%) patients in whom metastatic 
disease burden could be determined are shown in the 
appendix (p 1).
Standard hormone therapy was luteinising hormone­
releasing hormone analogues for 2046 (99%) men. 
Standard of care included docetaxel for 367 (18%) patients. 
Of 2061 patients undergoing random assignment, 
roughly half were nominated for each radiotherapy 
schedule, with 979 (48%) nominating the weekly schedule 
and 1082 (52%) the daily schedule. Of 968 patients 
assigned radiotherapy who started radio therapy within 
1 year after randomisation, 906 received their planned 
schedule and 62 received the alternative or another 
schedule. Two patients assigned radiotherapy received 
their planned schedule later than 1 year after ran­
domisation, and 62 did not receive radiotherapy at all 
(mainly because of patient’s choice). In patients who 
started radiotherapy, median time to starting radio therapy 
was 35 days (IQR 28–60) after randomisation, and 95 days 
(74–120) from starting hormone therapy (most patients 
started androgen deprivation therapy before random is­
ation; appendix p 2). Only 20 (2%) patients allocated to 
the control group received radiotherapy within 1 year of 
randomisation.
Median follow­up was 37 months (IQR 24–48). 
391 patients assigned to the control group died (median 
survival 46 months [IQR 27–not reached]; 3­year survival 
62%). Compared with controls, no survival advantage 
was noted with radiotherapy (stratified log­rank test 
p=0·451; HR 0·92, 95% CI 0·80–1·06; p=0·266), with 
370 deaths in the radiotherapy group (median survival 
48 months [IQR 27–not reached]; 3­year survival 65%; 
figure 2A; table 2). There was no evidence of non­
proportional hazards.
Figure 3 shows prespecified and exploratory subgroup 
analyses. In the analysis by metastatic burden, overall 
survival was improved in patients with low metastatic 
burden at baseline who were allocated radiotherapy 
(HR 0·68, 95% CI 0·52–0·90; p=0·007; 3­year survival 
73% with control vs 81% with radiotherapy; table 2), 
with no evidence of non­proportional hazards. We 
found some evidence of heterogeneity of treat ment effect 
by metastatic burden (interaction p=0·0098; figure 4). 
In patients with a high metastatic burden, there was 
no evidence of a treatment effect (HR 1·07, 95% CI 
0·90–1·28; p=0·420). The appendix (p 7) shows further 
exploratory consistency­of­effect analyses.
758 failure­free survival events were reported in patients 
assigned to the control group, largely driven by rising 
PSA (appendix p 3); median failure­free survival was 
13 months (IQR 6–33) and 3­year failure­free survival 
was 23%. In patients assigned to the radio therapy group, 
685 failure­free survival events were reported, with 
median failure­free survival of 17 months (IQR 8–53) and 
3­year failure­free survival of 32%. Overall, failure­free 
survival was improved with radiotherapy (HR 0·76, 
95% CI 0·68–0·84; p<0·0001; figure 2B). There was 
some evidence of non­proportional hazards (p=0·066). 
An analysis of restricted mean survival time found mean 
Deaths/N Deaths/N
Deaths/N Deaths/N
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Nodal status
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0
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B
Figure 3: Treatment effect on overall survival within selected baseline categories
HR=hazard ratio. PSA before androgen deprivation therapy (continuous), p=0·029; effect of adding radiotherapy 
is smaller with higher PSA. Patients with unknown T stage (TX), unknown N category (NX), or unknown Gleason 
sum score are not presented in the forest plot and do not contribute to interaction test results. Dotted line shows 
the overall hazard ratio. (A) Prespecified subgroup analyses. (B) Exploratory subgroup analyses.
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failure­free survival, restricted to the first 59 months 
on trial, was 21·4 months in the control group, 
compared with 26·2 months with radiotherapy (difference 
4·8 months, 95% CI 2·8–6·7; p<0·0001; table 2).
In the prespecified subgroup analysis by metastatic 
burden, failure­free survival was improved in patients 
with low metastatic burden at baseline who were allocated 
radiotherapy (HR 0·59, 95% CI 0·49–0·72; p<0·0001; 
table 2). Evidence of a differential treatment effect from 
radiotherapy compared with the high metastatic burden 
subgroup was also noted (interaction p=0·002; HR 0·88, 
95% CI 0·77–1·01; p=0·059; figure 4). The appendix (p 8) 
shows prespecified and exploratory consistency­of­effect 
analyses.
643 (84%) of 761 deaths were attributed to prostate 
cancer (329 [84%] of 391 in the control group and 
314 [85%] of 370 in the radiotherapy group). Adjusted 
competing risks regression for prostate cancer­specific 
survival using the Fine and Gray method provided no 
evidence of an overall treatment effect (sub­HR 0·94, 
95% CI 0·81–1·10; robust p=0·431; table 2). There was 
evidence of an effect in patients with low metastatic 
burden (sub­HR 0·65, 95% CI 0·47–0·90; robust 
p=0·010), but no evidence of a treatment effect was noted 
in patients with high metastatic burden (1·11, 0·92–1·33; 
robust p=0·279). A significant interaction was seen 
between treatment effect and metastatic burden (robustly 
estimated interaction p=0·007).
The appendix (pp 9, 10) shows the analysis of 
progression­free survival for all patients and by baseline 
metastatic burden. A treatment effect was only noted in 
patients with a low metastatic burden (HR 0·78, 95% CI 
0·63–0·98; p=0·033; table 2).
One or more symptomatic local events were reported by 
432 (42%) of 1029 patients allocated to the control group 
compared with 450 (44%) of 1032 patients assigned to the 
radiotherapy group. There was no evidence of a difference 
in time to first symptomatic local event by treatment 
allocation (HR 1·07, 95% CI 0·93–1·22; p=0·349; table 2). 
Table 3 shows the number of patients reporting each type 
of symptomatic local event at least once.
There was some evidence of heterogeneity in the 
effect on failure­free survival by nominated radiotherapy 
schedule (interaction p=0·072; appendix p 8). Prespecified 
A Overall survival in low metastatic burden
C Failure-free survival in low metastatic burden D Failure-free survival in high metastatic burden
B Overall survival in high metastatic burden
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Figure 4: Overall survival and failure-free survival by treatment and metastatic burden
HR=hazard ratio. Solid lines show the Kaplan-Meier analysis and dotted lines show the flexible parametric model.
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analyses in 1082 patients who nominated the daily 
schedule before randomisation (55 Gy in 20 fractions over 
4 weeks) found strong evidence of a failure­free survival 
advantage with radiotherapy compared with control 
(HR 0·69, 95% CI 0·59–0·80; p<0·0001). Among these 
1082 patients, 212 deaths were reported in the control 
group and 188 in the radiotherapy group (stratified log­
rank p=0·123; HR 0·86, 95% CI 0·71–1·05; p=0·128). 
There was insufficient evidence of a difference in failure­
free survival in 979 patients who nominated the weekly 
radiotherapy schedule (36 Gy in six fractions over 6 weeks; 
HR 0·85, 95% CI 0·73–0·99; p=0·033) to report on 
survival.
Adverse effects on the RTOG scale during radiotherapy 
were modest, with 48 (5%) of 920 patients allocated 
radiotherapy who started radiotherapy and who com­
pleted at least one acute toxicity form reporting grade 3 
or 4 adverse events; 43 (5%) patients reported their worst 
acute bladder toxic effect as grade 3 or 4, and eight (1%) 
reported their worst acute bowel toxic effect as grade 3 
or 4 (table 4; appendix p 11); no grade 5 toxic effects were 
reported. The incidence of acute bladder and bowel 
effects (grade 1–4) was lower for those who nominated 
the weekly radiotherapy sche dule than for those who 
nominated the daily schedule (282 [65%] bladder and 
206 [47%] bowel vs 341 [71%] bladder and 297 [62%] 
bowel). Patients in both control and radiotherapy groups 
reported a low incidence of grade 3 and 4 RTOG late 
effects (one [1%] control vs 37 [4%] radiotherapy; table 5).
The proportion of patients in the safety population 
reporting at least one severe adverse event of CTCAE 
grade 3 or worse was similar in both study groups and 
was dominated by side­effects associated with long­term 
hormone therapy (398 [38%] of 1050 in the control group 
and 380 [39%] of 985 in the radiotherapy group; appendix 
pp 4, 12); with no evidence of a difference in time to first 
grade 3 or worse event (HR 1·01, 95% CI 0·87–1·16; 
p=0·941). In 2028 patients with adverse event data at 
approximately 6 months, the proportions reporting a 
grade 3 or worse adverse event were similar (225 [21%] of 
1047 in the control group and 212 [22%] of 981 in the 
radiotherapy group). Of 1125 patients with adverse event 
data at 1 year, 63 (12%) of 531 patients in the control group 
and 78 (13%) of 594 in the radio therapy group reported a 
grade 3 or worse adverse event. At 2 years, of 533 patients 
with data available, 37 (15%) of 240 in the control group 
and 37 (13%) of 293 in the radiotherapy group reported a 
grade 3 or worse event. The pattern and levels of adverse 
events were very similar when considering the intention­
to­treat popu lation (data not shown). No deaths were 
reported as related to the research treatment.
The appendix (pp 13, 14) shows time to first new treat­
ment after failure­free survival event and time to first 
life­prolonging therapy (defined as available agents with 
proven survival gain in castration­resistant prostate 
cancer: docetaxel, abiraterone, cabazitaxel, enzalut­
amide, and radium 223). There was no evidence of any 
difference in time to any therapy, but an indication that 
patients allocated radiotherapy received a life­prolonging 
treatment sooner after disease pro gression but later 
Within treatment window After treatment window
Control 
(n=1029)
Radiotherapy 
(n=1032)
Control 
(n=1029)
Radiotherapy 
(n=1032)
Transurethral resection of the 
prostate
9 (1%) 13 (1%) 23 (2%) 24 (2%)
Ureteric stent 5 (<1%) 3 (<1%) 16 (2%) 7 (1%)
Surgery for bowel obstruction 0 (0%) 0 (0%) 0 (0%) 1 (<1%)
Urinary catheter 14 (1%) 18 (2%) 35 (3%) 36 (3%)
Nephrostomy 2 (<1%) 2 (<1%) 8 (1%) 3 (<1%)
Colostomy 0 (0%) 0 (0%) 2 (<1%) 1 (<1%)
Acute kidney injury 2 (<1%) 6 (1%) 31 (3%) 35 (3%)
Urinary tract infection 14 (1%) 31 (3%) 49 (5%) 75 (7%)
Urinary tract obstruction 4 (<1%) 7 (1%) 24 (2%) 17 (2%)
Prostate cancer death 2 (<1%) 1 (<1%) 327 (32%) 313 (30%)
Treatment window defined as 12 weeks from randomisation for patients in either treatment group who did not 
receive docetaxel, and 28 weeks from randomisation for those who did.
Table 3: Incidence of symptomatic local events reported before and after treatment period
Weekly schedule 
(n=437)
Daily schedule 
(n=483)
Total (n=920)
Bladder
Grade 0 152 (35%) 142 (29%) 294 (32%)
Grade 1 or 2 262 (60%) 318 (66%) 580 (63%)
Grade 3 or 4 20 (5%) 23 (5%) 43 (5%)
Missing 3 0 3
Bowel
Grade 0 231 (53%) 185 (38%) 416 (45%)
Grade 1 or 2 205 (47%) 290 (60%) 495 (54%)
Grade 3 or 4 1 (<1%) 7 (1%) 8 (1%)
Missing 0 1 1
RTOG=Radiation Therapy Oncology Group.
Table 4: Worst reported acute radiotherapy bladder and bowel toxic 
effect (RTOG scale) in patients allocated radiotherapy
Control (n=187)* Radiotherapy (n=988)
Diarrhoea 1 (1%) 12 (1%)
Proctitis 0 (0%) 11 (1%)
Cystitis 0 (0%) 7 (1%)
Haematuria 0 (0%) 6 (1%)
Rectal–anal stricture 0 (0%) 0 (0%)
Urethral stricture 0 (0%) 4 (<1%)
Rectal ulcer 0 (0%) 0 (0%)
Bowel obstruction 0 (0%) 1 (<1%)
Treatment groups correspond to the safety population. There were no reported 
grade 5 late radiotherapy toxic events. RTOG=Radiation Therapy Oncology Group. 
*Relates to patients assigned control who had some radiotherapy at some point.
Table 5: Grade 3 or 4 worst late radiotherapy toxicity score (RTOG scale) 
in patients who received radiotherapy (for research or progression)
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after randomisation than did patients allocated control 
(figure 5; appendix pp 13, 14). Overall exposure to 
treatment for progression is summarised in the 
appendix (p 5).
Discussion
This randomised comparison of more than 2000 pat­
ients with metastatic prostate cancer showed that local 
radiotherapy to the prostate did not improve overall 
survival for unselected patients. However, a prespecified 
analysis showed that prostate radiotherapy did improve 
overall survival (from 73% to 81% at 3 years) in those 
with a low metastatic burden, which represented 40% of 
the comparison population.
Our subgroup finding meets all criteria proposed by 
Sun and colleagues to assess credibility of subgroup 
effects:20 low metastatic burden status was deter­
mined from scans taken before randomisation; the 
hypothesis—including the direction of the effect—was 
specified a priori; only a few hypothesised subgroup 
effects were tested; the interaction test suggested a low 
likelihood that the apparent subgroup effect could be 
accounted for by chance; the subgroup effect was 
independent of other assessed variables; the size of the 
subgroup effect was large (HR 0·68 for low metastatic 
burden and HR 1·07 high metastatic burden); and the 
interaction was consistent both with other related 
outcome measures in STAMPEDE (eg, failure­free 
survival) and with the interaction reported on number 
of bone metastases in the HORRAD trial12 (less than five 
bone metastases, HR 0·68; five or more bone meta­
stases, HR 1·06). It also seems plausible that the effect 
of local radio therapy would be diminished in patients 
with a greater burden of metastatic disease. There is, 
therefore, good reason to accept that prostate radio­
therapy improves survival of men with a low metastatic 
burden and that it should now be a standard treatment. 
Unlike many other new interventions for metastatic 
cancer, prostate radiotherapy does not require regulatory 
approval and is readily available at modest cost in most 
parts of the world.
When this comparison was designed, the standard 
radical radiotherapy dose schedule for localised prostate 
cancer was 74 Gy in 37 fractions over 7·5 weeks. It was 
felt that this schedule would be too burdensome for 
patients with metastatic disease, and the two more 
convenient schedules permitted in the trial were chosen 
based on a survey of investigators’ opinions. The trial has 
proven the principle that local radiotherapy can improve 
survival, but the optimum dose schedule and technique 
are uncertain. Radical radiotherapy for localised prostate 
cancer is now typically given to a dose of 60 Gy in 
20 fractions over 4 weeks.21 With contemporary tech­
niques for target delineation and treatment delivery, this 
schedule is well tolerated21 and might be expected to be at 
least as effective as the two schedules tested in the trial.
It is well known that prostate radiotherapy improves 
survival for men with locally advanced (T3–4 N0 M0) 
prostate cancer.22 We have now found that prostate 
radiotherapy also improves survival for men with a 
low metastatic burden (Tany Nany M1) prostate cancer. It 
therefore seems safe to conclude that radiotherapy would 
also improve survival for men with pelvic node­positive 
prostate cancer (Tany N1 M0). This is important, because it 
is not feasible to do randomised trials specifically in men 
with non­metastatic node­positive prostate cancer and 
because such men often receive systemic treatment 
alone. In the current study, roughly 60% of patients were 
N1 in both the high and low metastatic burden subgroups. 
The benefit we have shown for prostate radiotherapy 
in prostate cancer with a low metastatic burden also 
raises another question: would there be further benefit 
from additional radiotherapy to the oligometastases 
themselves?
Low metastatic burden disease is sometimes known as 
oligometastatic. Although this term is widely used, it is 
imprecise and potentially misleading because it implies 
only a small number of metastases. Patients with low 
metastatic burden disease, according to the CHAARTED 
definition, may have an unlimited number of metastases 
provided they are confined to lymph nodes and the axial 
skeleton. 
Our data have several strengths to note. This is a large 
randomised dataset with broad engagement from more 
than 100 hospitals across Switzerland and the UK. 
By incorporating the comparison into the established 
STAMPEDE protocol, following peer­review and protocol 
amendment, we recruited to an enlarged target well 
ahead of schedule (2061 patients in 3·5 years rather than 
1250 patients in 4 years).
Our data also have some limitations. First, the possible 
clinical relevance of metastatic burden in patients with 
prostate cancer only became widely apparent when the 
CHAARTED trial reported.15 We determined metastatic 
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Figure 5: Time from randomisation to life-prolonging therapy
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burden by retrospectively collecting retrievable baseline 
scans. This was possible in most (94%) but not all 
patients. Second, compliance with allocation to prostate 
radiotherapy was not complete (94%) and this could 
underestimate the true effect size for radiotherapy. Third, 
median follow­up (37 months) is shorter than median 
survival (46 months); this could be particularly relevant to 
the analysis of symptomatic local events, which can occur 
late and after disease progression. We plan to continue 
follow­up and to link to routinely collected electronic 
health records to capture symptom atic local events. Our 
current analysis indicates that radiotherapy does not 
improve survival for patients with a high metastatic 
burden. Future analyses will explore whether prostate 
radiotherapy might still be useful in such patients for 
prevention of symptomatic local events. Fourth, up­front 
systemic treatment of meta static prostate cancer has 
evolved. Most patients in this comparison received 
androgen deprivation alone. Doce taxel was permitted in 
addition to hormone therapy after its approval in the 
UK15,23,24 and was used, therefore, mostly in recently 
randomised patients who had the shortest follow­up. 
Although only roughly one in six patients received 
docetaxel in this comparison, there is no evidence to 
suggest that prostate radiotherapy is more or less effective 
when docetaxel is given in addition to androgen 
deprivation therapy. More recently, abiraterone has 
become another option in this setting.25–28 The value of 
prostate radiotherapy in men receiving abiraterone is 
being tested in the PEACE1 trial (NCT01957436),29 and the 
prospectively planned STOPCAP M1 meta­analysis of 
these trials will explore this further.30
We have tested local treatment to the prostate using 
radiotherapy. It is possible that other forms of local 
treatment—such as radical prostatectomy—might also 
be effective. If the benefit of radiotherapy is mediated by 
local tumour eradication, one would expect surgery to be 
at least as effective. However, radiotherapy might be 
effective via other mechanisms (eg, immune modu­
lation), so the role of surgery in men with metastatic 
prostate cancer remains unproven. The feasibility of 
prostate surgery in this setting is being tested in the 
g­RAMMP trial (NCT02454543) and the TROMBONE 
feasibility study.31
There is uncertainty regarding the optimum defini tion 
of low metastatic burden (oligometastatic) prostate 
cancer. We used the same definition as that in the 
CHAARTED trial, but this is not necessarily the optimum 
definition. Our findings were almost identical when 
applying a variant of the definition used in the LATITUDE 
trial;25 absence of visceral metastases and fewer than 
three bone metastases (data not shown). Exploratory 
analyses of a broader cohort of patients in the STAMPEDE 
study will inform the definition of oligometastatic 
disease, with the aim of refining patients’ selection for 
prostate radiotherapy. All current definitions are based 
on conventional imaging using CT and bone scans. 
Caution will be required in extrapolating these results to 
patients imaged with more sensitive techniques (eg, 
PSMA PET). For example, patients with low meta static 
burden on conventional imaging should not be denied 
prostate radiotherapy because they have additional 
lesions identified on a PET scan.
In summary, radiotherapy to the prostate did not 
improve survival for unselected patients with newly 
diagnosed metastatic prostate cancer, but, in a pre­
specified subgroup analysis, overall survival did improve 
in men with a low metastatic burden. Therefore, 
prostate radiotherapy should be a standard treatment 
option for men with a low metastatic burden. These 
findings also raise the possibility that local treatment to 
the primary tumour should be explored for patients 
with small­volume metastatic disease from other 
malignant diseases.
Contributors
CCP was comparison chief investigator. NDJ was protocol chief 
investigator. CCP, MRS, NDJ, MDM, DPD, NWC, and MKBP 
contributed to comparison design. CLA contributed to trial operations. 
APH, AA, and NWC collated and reviewed bone and CT scans. 
HD reviewed bone and CT scans. MRS, CDB, CCP, MRG, NWC, MKBP, 
NDJ, APH, and AA contributed to the analysis plan. CDB, MRS, APH, 
and AA did analyses. CCP, CDB, MRS, NDJ, MKBP, NWC, APH, and 
AA contributed to writing of the report. The Trial Management Group 
consisted of NDJ (chair), MDM, and NWC (vice chairs), and MKBP, 
MRS, DPD, NWC, AWSR, REL, GNT, WC, SG, ZIM, SC, CCP, GA, DM, 
JMR, and RJJ. All authors collated and interpreted data, and edited, 
reviewed, and approved the final report.
Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of 
Drug Efficacy (STAMPEDE) investigators
Independent Oversight Committee Members: Independent Data Monitoring 
Committee—John Yarnold (chair), Ronald de Wit, Bertrand Tombal 
(previous: Doug Altman, Reg Hall, Chris Williams); Independent members 
of Trial Steering Committee: Jonathan Ledermann (chair), Jan Erik 
Damber, Richard Emsley, Alan Horwich (previous: John Fitzpatrick, 
David Kirk, Jim Paul).  
Participating Site List (hospital [n patients during recruitment window: 
recruiting investigators])—Addenbrooke’s Hospital (7: D Mazhar); 
Ashford William Harvey Hospital (10: C Thomas, N Mithal, A Edwards); 
Aylesbury, Stoke Mandeville Hospital (4: T Pwint, P Camilleri); Ayr 
Hospital (15: H Glen, J Ansari); Barnet General Hospital 
(15: U McGovern, A Eichholz); Basingstoke & North Hampshire 
Hospital (7: R Shaffer); Bath, Royal United Hospital (34: O Frim, 
M Beresford, P Kehagioglou); Belfast City Hospital (64: J O’Sullivan, 
D Mitchell, S Jain, P L Shum); Birmingham, City Hospital (14: D Ford); 
Birmingham, Good Hope Hospital (10: D Ford); Birmingham, 
Heartlands Hospital (11: A Zarkar); Birmingham, Queen Elizabeth 
(36: N James); Blackburn, East Lancashire Trust (52: O Parikh, 
N Charnley); Bolton, Royal Bolton Hospital (11: T Elliott); Boston, 
Pilgrim Hospital (18: M Panades, D Ballesteros­Quintail); Bournemouth, 
Royal Bournemouth Hospital (23: S Brock); Bradford Royal Infirmary 
(20: S Brown); Brighton, Royal Sussex County Hospital (17: A Robinson, 
G Plantaniotis); Bristol Haematology & Oncology Centre (58: A Bahl, 
C Herbert, S Masson); Burton, Queen’s Hospital (40: M Smith­Howell, 
S Chetiyawardana, P Pattu); Bury St Edmunds, West Suffolk Hospital 
(14: C Woodward, Y Rimmer); Cardiff, Velindre (86: J Lester, J Staffurth, 
J Barber, S Kumar, N Palaniappan, M Button, J Tanguay); Chelmsford, 
Broomfield Hospital (24: A Hamid); Cheltenham General Hospital 
(33: J Bowen, S Jonnada, P Jenkins); Chester, Countess of Chester 
Hospital (26: A Ibrahim); Coventry & Warwickshire, University Hospital 
(26: J Worlding, A Stockdale); Crewe, Leighton Hospital (22: J Wylie); 
Cumbria, Cumberland Infirmary (8: A Kumar); Darlington Memorial 
Hospital (26: M Kagzi, J Hardman, C Peedell); Derby, Royal Derby 
Hospital (43: P Chakraborti); Devon, North Devon District Hospital 
Articles
2364 www.thelancet.com   Vol 392   December 1, 2018
(16: D Sheehan, P Stephens); Doncaster Royal Infirmary (25: V Sivoglo, 
C Ferguson, M Alzouebi); Dorset County Hospital (2: P Crellin); 
Dudley, Russells Hall Hospital (20: P Keng­Koh, S Tirmazy); Eastbourne 
District General Hospital (12: F McKinna); Edinburgh, Western General 
(40: D McLaren); Essex County Hospital (31: D Muthukumar, B Sizer, 
M Kumar); Exeter, Royal Devon & Exeter NHS Foundation Trust 
(59: D Sheehan, R Srinivasan, V Ford); Gillingham, Medway Hospital 
(19: H Taylor); Glangwili General Hospital (2: M D Phan); Glasgow, 
Beatson West of Scotland Cancer Centre (64: B Venugopal; J Wallace, 
R Jones, C Lamb); Guildford, Royal Surrey County Hospital (45: R Laing, 
S Khaksar, K Wood, J Money­Kyrle); Harlow, Princess Alexandra 
Hospital (16: N Gupta, L Melcher); Hereford County Hospital 
(22: W Grant, A Cook); Huddersfield Royal Infirmary (32: U Hofmann); 
Hull, Castle Hill Hospital (33: M Simms, J Hetherington); Inverness, 
Raigmore Hospital (26: N McPhail, C MacGregor); Ipswich Hospital 
(36: R Venkitaraman, C Scrase); Keighley, Airedale Hospital 
(24: S Brown); Kent and Canterbury Hospital (24: C Thomas, R Raman, 
N Mithal); Kent, Queen Elizabeth Queen Mother Hospital 
(14: R Raman); Kidderminster General Hospital (13: L Capaldi, 
M Churn); Larbert, Forth Valley Royal Hospital (16: N Sidek); Leeds, 
St James University Hospital (55: W Cross, C Loughrey, S Jagdev, 
A Henry, D Bottomley, S Prescott, A Paul); Lincoln County Hospital 
(25: T Sreenivasan, D Ballesteros­Quintail, M Panades); Liverpool, Royal 
Liverpool University Hospital (30: Z Malik, C Eswar); Liverpool, 
University Hospital Aintree (7: P Robson); London, Charing Cross 
Hospital (27: A Falconer, S Mangar); London, Guy’s Hospital 
(47: S Chowdhury, S Morris); London, North Middlesex Hospital 
(11: J Newby, A Thompson, L Melcher, M Singhera); London, Royal Free 
Hospital (10: M Vilarino­Varela, K Pigott, N Rosenfelder); London, 
St Bartholomew’s Hospital (7: P Wells, K Tipples); London, St George’s 
Hospital (21: L Pickering); London, University College Hospital 
(14: U McGovern, H Payne); Maidstone, Kent Oncology Centre 
(40: H Taylor, K Lees, A Clarke, S Beesley); Manchester Christie Hospital 
(51: N Clarke, T Elliott, J Livsey, J Wylie, R Conroy, A Choudhury, A Tran, 
J Logue); Manchester, Royal Oldham Hospital (22: J Livsey, 
A Choudhury); Manchester, Salford Royal Hospital (18: N Clarke, 
T Elliot); Middlesbrough, James Cook University Hospital (28: C Peedell, 
H Van der Voet, J Hardman); Newcastle, Freeman Hospital 
(63: A Azzabi, R McMenemin, J Frew); North Staffordshire University 
Hospital (21: F Adab, S Vengalil, R Bhana); Northwood, Mount Vernon 
Hospital (58: P Hoskin, P Ostler, R Alonzi, C Westbury, R Hughes, 
N Anyamene); Nottingham University Hospitals, City Campus 
(32: S Sundar, J Mills, G Walker, E Chadwick); Nuneaton, George Eliot 
Hospital (4: A Chan); Oxford, Churchill Hospital (35: A Protheroe, 
D Cole, A Sabharwal, M Tuthill); Poole Hospital (24: J Davies); 
Portsmouth, Queen Alexandra Hospital (81: J Gale); Preston, Royal 
Preston Hospital (54: A Birtle, O Parikh, M Wise, N Charnley); Reading, 
Royal Berkshire Hospital (10: P Rogers, H O’Donnell); Redditch, 
Alexandra Hospital (12: B Kurec, J Hamilton); Romford, Queen’s 
Hospital (30: S Gibbs, K Tarver); Royal Hampshire Hospital (2: S Paisey); 
Scarborough General Hospital (29: M Hingorani); Sheffield, Weston 
Park (55: C Ferguson, O Din, M Alzouebi, L Evans, T Das); Shrewsbury, 
Royal Shrewsbury Hospital (50: N Srihari, R Prashant); Somerset, 
Weston General Hospital (7: S Hilman); Southampton General Hospital 
(28: C Heath, M Wheater, S Crabb); Southend University Hospital 
(28: D Tsang, I Ahmed, O Chan); Southport and Formby District General 
Hospital (10: N Bhalla); St Leonards­on­Sea, Conquest Hospital 
(4: F McKinna, K Lees); Stevenage, Lister Hospital (10: R Hughes); 
Stockport, Stepping Hill Hospital (39: J Logue, C Coyle); 
Stockton­on­Tees, University Hospital North Tees (21: D Leaning, 
D Shakespeare); Sunderland Royal Hospital (10: A Azzabi, I Pedley, 
S Iqbal); Sutton­in­Ashford, King’s Mill Hospital (26: D Saunders, 
G Walker); Sutton, Royal Marsden Hospital (58: D Dearnaley, N Van As, 
C Parker, V Khoo); Swansea, Singleton (53: D Pudney, J Wagstaff, 
M D Phan); Swindon, Great Western Hospital (23: O Khan, D Cole); 
Taunton, Musgrove Park Hospital (33: E Gray, J Graham, M Varughese); 
Torbay District General Hospital (32: A Lydon, R Srinivasan); Tyne and 
Wear, South Tyneside District Hospital (2: A Azzabi); Warrington 
Hospital (35: I Syndikus, S Tolan); Warwick Hospital (11: A Stockdale); 
Wigan, Royal Albert Edward Infirmary (10: A Tran); Bebington (Wirral), 
Clatterbridge Centre for Oncology (36: S Tolan, I Syndikus, N Bhalla, 
A Ibrahim, A Montazeri, J Littler); Wolverhampton, New Cross Hospital 
(31: S Tirmazy, I Sayers); Woolwich, Queen Elizabeth Hospital 
(5: S Hughes); Worcestershire Royal Hospital (18: L Capaldi, J Bowen); 
Worthing Hospital (21: A Nikapota, G Plataniotis); Wycombe Hospital 
(19: P Camilleri, A Sabharwal, T Pwint, G Andrade); Yeovil District 
Hospital (3: E Gray, G Sparrow); York Teaching Hospital (8: J Joseph, 
D Bottomley); Basel Universitatsspital (3: C Rentsch); Berne University 
Hospital [Inselspital] (4: G Thalmann); Chur Kantonsspital Graubunden 
(13: R Strebel, R Cathomas); Istituto Oncologico della Svizzera Italiana 
(2: E Roggero); Kantonsspital St Gallen (5: D Engeler); Lausanne, Centre 
Hospital University Vaudois (3: D Berthold); and more than 3000 local 
site team staff across these hospitals.  
Medical Research Council Clinical Trials Unit at University College 
London—Statisticians: Matthew Sydes, Max Parmar, Chris Brawley, 
Fiona Ingleby, Adrian Cook (previous: Gordana Jovic, Patrick Royston, 
Babak Choodari­Oskooei, Daniel Bratton, Andrew Embleton, 
Melissa Gannon [nee Spears]); Project and Trial Managers: Claire Amos, 
Nafisah Atako, Cheryl Pugh, Claire Murphy, Joanna Calvert, 
Mazna Anjum, Chris Wanstall, Arlen Wilcox, Charlotte Tyson, 
Michelle Buckner, Dymphna Lee (previous: Charlene Green, 
Francesca Schiavone, Katie Ward, Anna Herasimtschuk, Jenny Petrie, 
Alanna Brown, Orla Prendiville, Shabinah Ali); Data Managers: 
Carly Au, Lina Bergstrom, Tasmin Philips, Steph Wetton, Saba Khan, 
Amy Fiddament, Georgia Mannion­Krase, Hannah Sweeney (previous: 
Charlene Green, Elizabeth Clark, Sara Peres, Hannah Gardner, 
Dominic Hague, Katie Ward, Peter Vaughan, Eva Ades, Hannah Babiker, 
Zohrah Khan, Nargis Begum, Saba Khan, Jenna Grabey, 
Danielle Johnson); Data Scientists and Programmers: Nadine Van Looy, 
Zaheer Islam, Dominic Hague, Carly Au (previous: Lindsey Masters, 
Will Cragg, Sajad Khan); Clinicians: Clare Gilson, Alastair Ritchie; Trial 
Assistants: Stephanie Wetton, Amy Fiddament (previous: Leigh Dobson, 
Alexandra Wadia, Nat Thorogood, Shanaz, Sohail, Tracey Fisher, 
Andrew Whitney, Elizabeth Adesanya).  
Swiss Group for Cancer Clinical Research—Project and Trial Managers: 
Eloïse Kremer, Corinne Schar (previous: Estelle Cassolly).
Declaration of interests
GA reports personal fees from Veridex, Novartis, Millennium 
Pharmaceuticals, Takeda, and Sanofi­Aventis, outside the submitted 
work; personal fees and non­financial support from Roche/Ventana, 
Astellas, Medivation, Pfizer, Abbott Laboratories, Essa Pharmaceuticals, 
and Bayer Healthcare Pharmaceuticals, outside the submitted work; 
grants from AstraZeneca, Arno Therapeutics, and Innocrin Pharma, 
outside the submitted work; grants, personal fees, and non­financial 
support from Janssen, outside the submitted work; and personal fees 
and other from the Institute of Cancer Research, outside the submitted 
work. ABi reports advisory board fees from Astellas, during the conduct 
of the study; personal fees, speaker fees, and advisory board fees from 
Sanofi, during the conduct of the study; personal fees and advisory board 
fees from Janssen, during the conduct of the study; and advisory board 
fees from Bayer and AstraZeneca, outside the submitted work. 
SC reports personal fees from Janssen Pharmaceutical, outside the 
submitted work. NWC reports personal fees from Janssen, during the 
conduct of the study and outside the submitted work. WC reports 
personal fees from Janssen, outside the submitted work; and advisory 
board fees from Bayer, outside the submitted work. DPD reports grants 
and other from the National Institute for Health Research Biomedical 
Research Centre at the Royal Marsden NHS Foundation Trust and the 
Institute of Cancer Research, during the conduct of the study; grants 
from Cancer Research UK (programme grant C46/A10588, C33589/
A19727), during the conduct of the study; personal fees from Amgen, 
Astellas, Takeda, Sandoz, Janssen, and the Institute of Cancer Research 
(share of royalties for abiraterone), outside the submitted work; and has 
a patent (EP1933709B1) issued. SG reports personal fees and honoraria 
to her hospital from AAA International, Roche, Orion, and Sanofi, 
outside the submitted work; honoraria to her hospital from Bayer, 
Clovis, CureVac, Astellas, Bristol­Myers Squibb, Janssen, Ferring, 
Innocrin Pharmaceuticals, Novartis, and Cell Search, outside the 
submitted work; uncompensated advisory role for Nectar Therapeutics 
and ProteoMediX, outside the submitted work; and personal fees from 
MaxiVax SA, outside the submitted work. CG reports grants from Clovis 
Oncology, outside the submitted work. NDJ reports advisory board fees 
Articles
www.thelancet.com   Vol 392   December 1, 2018 2365
from Sanofi and Novartis, outside the submitted work; and grants, 
personal fees, non­financial support, advisory board fees, speaker fees, 
and travel fees from Janssen, outside the submitted work. RJJ reports 
personal fees and non­financial support from Janssen, outside the 
submitted work; grants, personal fees, research funding, honoraria, 
speaker fees, and advisory board fees from Astellas, outside the 
submitted work; and personal fees and advisory board fees from Sanofi 
and Novartis, outside the submitted work. JFL reports personal fees, 
non­financial support, advisory board fees, and travel fees from Janssen, 
Astellas, and Sanofi, outside the submitted work. ZIM reports personal 
fees, consultancy, advisory board fees, honoraria, and travel fees from 
Janssen and Sanofi, outside the submitted work; advisory board fees, 
honoraria, and travel fees from Astellas, outside the submitted work; 
and travel fees from Bayer, outside the submitted work. MDM reports 
personal fees, speaker fees, and advisory board fees from Sanofi, outside 
the submitted work; and personal fees from Janssen and Bayer, outside 
the submitted work. JMO’S reports advisory board fees from Sanofi, 
outside the submitted work; personal fees, speaker fees, and advisory 
board fees from Janssen and Astellas, outside the submitted work; and 
speaker fees, advisory board fees, and research funding from Bayer, 
outside the submitted work. CCP reports a research grant, personal fees, 
and advisory board fees from Bayer, outside the submitted work; 
advisory board fees from AAA, outside the submitted work; and personal 
fees and speaker fees from Janssen, outside the submitted work. 
MKBP reports educational grants from Astellas, Clovis Oncology, 
Novartis, Pfizer, and Sanofi, outside the submitted work. DJS reports 
fees for meeting attendance from Astellas and Ipsen, outside the 
submitted work. NNS reports personal fees from Janssen, Pfizer, Sanofi, 
Merck Sharpe & Dohme, and Roche, outside the submitted work. 
MRS reports grants and non­financial support from Astellas, Clovis 
Oncology, Novartis, Pfizer, and Sanofi, outside the submitted work; 
personal fees from Eli Lilly, outside the submitted work; and grants, 
personal fees and non­financial support from Janssen, outside the 
submitted work. AA, RA, CLA, ABa, CDB, OD, HD, CE, JG, MRG, APH, 
SJ, SK, REL, DM, RM, OAP, IDP, DMP, AWSR, GNT, ATHT, and JMR 
declare no competing interests.
Acknowledgments
This trial was funded by Cancer Research UK (CRUK_A12459), UK 
Medical Research Council (MRC_MC_UU_12023/25), and the Swiss 
Group for Clinical Cancer Research. Research support for the protocol 
was provided by Cancer Research UK (CRUK_A12459), UK Medical 
Research Council (MRC_MC_UU_12023/25), the Swiss Group for 
Clinical Cancer Research, Astellas, Clovis Oncology, Janssen, Novartis, 
Pfizer, and Sanofi­Aventis. This Article represents independent research 
part­funded by the National Institute for Health Research (NIHR) 
Biomedical Research Centre at the Royal Marsden NHS Foundation 
Trust and the Institute of Cancer Research. The views expressed in this 
Article are those of the authors and not necessarily those of the National 
Health Service, the NIHR, or the Department of Health. We thank 
Fiona Ingleby and Adrian Cook (Medical Research Council Clinical 
Trials Unit at University College London) for reviewing analyses.
References
1 Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1­positive 
haematopoietic bone marrow progenitors initiate the pre­metastatic 
niche. Nature 2005; 438: 820–27.
2 McAllister SS, Gifford AM, Greiner AL, et al. Systemic endocrine 
instigation of indolent tumor growth requires osteopontin. Cell 2008; 
133: 994–1005.
3 Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy 
followed by interferon alfa­2b compared with interferon alfa­2b alone 
for metastatic renal­cell cancer. N Engl J Med 2001; 345: 1655–59.
4 Mickisch GHJ, Garin A, van Poppel H, de Prijck L, Sylvester R. 
Radical nephrectomy plus interferon­alfa­based immunotherapy 
compared with interferon alfa alone in metastatic renal­cell 
carcinoma: a randomised trial. Lancet 2001; 358: 966–70.
5 Mejean A, Ravaud A, Thezenas S, et al. Sunitinib alone or after 
nephrectomy in metastatic renal­cell carcinoma. N Engl J Med 2018; 
379: 417–27.
6 Slotman BJ, van Tinteren H, Praag JO, et al. Use of thoracic 
radiotherapy for extensive stage small­cell lung cancer: a phase 3 
randomised controlled trial. Lancet 2015; 385: 36–42.
7 Badwe R, Hawaldar R, Nair N, et al. Locoregional treatment versus 
no treatment of the primary tumour in metastatic breast cancer: 
an open­label randomised controlled trial. Lancet Oncol 2015; 
16: 1380–88.
8 Culp SH, Schellhammer PF, Williams MB. Might men diagnosed 
with metastatic prostate cancer benefit from definitive treatment of 
the primary tumor? A SEER­based study. Eur Urol 2014; 
65: 1058–66.
9 Fossati N, Trinh QD, Sammon J, et al. Identifying optimal 
candidates for local treatment of the primary tumor among patients 
diagnosed with metastatic prostate cancer: a SEER­based study. 
Eur Urol 2015; 67: 3–6.
10 Gratzke C, Engel J, Stief CG. Role of radical prostatectomy in 
metastatic prostate cancer: data from the Munich Cancer Registry. 
Eur Urol 2014; 66: 602–03.
11 Rusthoven CG, Jones BL, Flaig TW, et al. Improved survival with 
prostate radiation in addition to androgen deprivation therapy for 
men with newly diagnosed metastatic prostate cancer. 
J Clin Oncol 2016; 34: 2835–42.
12 Boevé LMS, Hulshof MCCM, Vis AN, et al. Effect on survival of 
androgen deprivation therapy alone compared to androgen 
deprivation therapy combined with concurrent radiation therapy to 
the prostate in patients with primary bone metastatic prostate 
cancer in a prospective randomised clinical trial: data from the 
HORRAD trial. Eur Urol 2018; published online Sept 25. 
DOI:10.1016/j.eururo.2018.09.008.
13 Parker CC, Sydes MR, Mason MD, et al. Prostate radiotherapy for 
men with metastatic disease: a new comparison in the STAMPEDE 
trial. Clin Oncol 2013; 25: 318–20.
14 Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy 
Oncology Group (RTOG) and the European organization for 
research and treatment of cancer (EORTC). 
Int J Radiat Oncol Biol Phys 1995; 31: 1341–46.
15 Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy 
in metastatic hormone­sensitive prostate cancer. N Engl J Med 2015; 
373: 737–46.
16 Sydes MR, Parmar MK, Mason MD, et al. Flexible trial design in 
practice: stopping arms for lack­of­benefit and adding research 
arms mid­trial in STAMPEDE—a multi­arm multi­stage 
randomized controlled trial. Trials 2012; 13: 168.
17 Barthel FM­S, Royston P, Parmar MKB. A menu­driven facility for 
sample­size calculation in novel multiarm, multistage randomized 
controlled trials with a time­to­event outcome. Stata J 2009; 9: 505.
18 Royston P, Parmar MKB. The use of restricted mean survival time 
to estimate the treatment effect in randomized clinical trials when 
the proportional hazards assumption is in doubt. Stat Med 2011; 
30: 2409–21.
19 Gray R. A class of K­sample tests for comparing the cumulative 
incidence of a competing risk. Ann Stat 1988; 16: 1141–54.
20 Sun X, Briel M, Walter SD, Guyatt GH. Is a subgroup effect 
believable? Updating criteria to evaluate the credibility of subgroup 
analyses. BMJ 2010; 340: c117.
21 Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus 
hypofractionated high­dose intensity­modulated radiotherapy for 
prostate cancer: 5­year outcomes of the randomised, non­inferiority, 
phase 3 CHHiP trial. Lancet Oncol 2016; 17: 1047–60.
22 Warde P, Mason M, Ding K, et al. Combined androgen deprivation 
therapy and radiation therapy for locally advanced prostate cancer: 
a randomised, phase 3 trial. Lancet 2011; 378: 2104–11.
23 James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, 
zoledronic acid, or both to first­line long­term hormone therapy in 
prostate cancer (STAMPEDE): survival results from an adaptive, 
multiarm, multistage, platform randomised controlled trial. 
Lancet 2016; 387: 1163–77.
24 Vale CL, Burdett S, Rydzewska LHM, et al. Addition of docetaxel or 
bisphosphonates to standard of care in men with localised or 
metastatic, hormone­sensitive prostate cancer: a systematic review 
and meta­analyses of aggregate data. Lancet Oncol 2016; 17: 243–56.
25 Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in 
metastatic, castration­sensitive prostate cancer. N Engl J Med 2017; 
377: 352–60.
26 James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate 
cancer not previously treated with hormone therapy. 
N Engl J Med 2017; 377: 338–51.
Articles
2366 www.thelancet.com   Vol 392   December 1, 2018
27 Rydzewska LHM, Burdett S, Vale CL, et al. Adding abiraterone to 
androgen deprivation therapy in men with metastatic 
hormone­sensitive prostate cancer: a systematic review and 
meta­analysis. Eur J Cancer 2017; 84: 88–101.
28 Sydes MR, Spears MR, Mason MD, et al. Adding abiraterone or 
docetaxel to long­term hormone therapy for prostate cancer: directly 
randomised data from the STAMPEDE multi­arm, multi­stage 
platform protocol. Ann Oncol 2018; 29: 1235–48.
29 Fizazi K, Abrahamsson PA, Ahlgren G, et al. Achievements and 
perspectives in prostate cancer phase 3 trials from genitourinary 
research groups in Europe: introducing the Prostate Cancer 
Consortium in Europe. Eur Urol 2015; 67: 904–12.
30 Burdett S, Tierney J, Fisher D, et al. A systematic review and 
meta­analysis of the effects of radiotherapy for metastatic 
hormone­sensitive prostate cancer. PROSPERO 2018 
CRD42018096108. https://www.crd.york.ac.uk/PROSPERO/display_
record.php?RecordID=96108 (accessed Oct 6, 2018).
31 Sooriakumaran P. Testing radical prostatectomy in men with 
prostate cancer and oligometastases to the bone: a randomized 
controlled feasibility trial. BJU Int 2017; 120: E8–20.
